title: Continued response off treatment after BRAF inhibition in refractory hairy cell leukemia.
authors.affiliation: Department of Translational Oncology, German Cancer Research Center, Heidelberg, Germany. thorsten.zenz@nct-heidelberg.de
authors.forename: Sascha
authors.initials: S
authors.lastname: Dietrich
authors.forename: Jennifer
authors.initials: J
authors.lastname: Hüllein
authors.forename: Michael
authors.initials: M
authors.lastname: Hundemer
authors.forename: Nicola
authors.initials: N
authors.lastname: Lehners
authors.forename: Alexander
authors.initials: A
authors.lastname: Jethwa
authors.forename: David
authors.initials: D
authors.lastname: Capper
authors.forename: Till
authors.initials: T
authors.lastname: Acker
authors.forename: Boyan K
authors.initials: BK
authors.lastname: Garvalov
authors.forename: Mindaugas
authors.initials: M
authors.lastname: Andrulis
authors.forename: Carolin
authors.initials: C
authors.lastname: Blume
authors.forename: Christoph
authors.initials: C
authors.lastname: Schulte
authors.forename: Thomas
authors.initials: T
authors.lastname: Mandel
authors.forename: Julia
authors.initials: J
authors.lastname: Meissner
authors.forename: Stefan
authors.initials: S
authors.lastname: Fröhling
authors.forename: Christof
authors.initials: C
authors.lastname: von Kalle
authors.forename: Hanno
authors.initials: H
authors.lastname: Glimm
authors.forename: Anthony D
authors.initials: AD
authors.lastname: Ho
authors.forename: Thorsten
authors.initials: T
authors.lastname: Zenz
mesh_terms: D058846:Antibodies, Monoclonal, Murine-Derived / Q000008:administration & dosage; D000971:Antineoplastic Combined Chemotherapy Protocols / Q000494:pharmacology / Q000627:therapeutic use*; D017338:Cladribine / Q000008:administration & dosage; D019008:Drug Resistance, Neoplasm; D005434:Flow Cytometry; D018698:Glutamic Acid; D006801:Humans; D007211:Indoles / Q000008:administration & dosage / Q000009:adverse effects / Q000494:pharmacology* / Q000627:therapeutic use*; D060828:Induction Chemotherapy; D007943:Leukemia, Hairy Cell / Q000175:diagnosis / Q000188:drug therapy* / Q000235:genetics*; D008297:Male; D008875:Middle Aged; D058990:Molecular Targeted Therapy; D017354:Point Mutation; D048493:Proto-Oncogene Proteins B-raf / Q000037:antagonists & inhibitors* / Q000235:genetics; D000069283:Rituximab; D013449:Sulfonamides / Q000008:administration & dosage / Q000009:adverse effects / Q000494:pharmacology* / Q000627:therapeutic use*; D016896:Treatment Outcome; D014633:Valine; D000077484:Vemurafenib
chemical_list: D058846:Antibodies, Monoclonal, Murine-Derived; D007211:Indoles; D013449:Sulfonamides; D000077484:Vemurafenib; D018698:Glutamic Acid; D017338:Cladribine; D000069283:Rituximab; C482119:BRAF protein, human; D048493:Proto-Oncogene Proteins B-raf; D014633:Valine